Research Overview
Thymosin Alpha-1 (Ta1) is a 28-amino-acid N-terminally acetylated polypeptide originally isolated from thymic tissue and characterised by Goldstein and colleagues in the 1970s. The sequence Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN corresponds to a fragment of the larger prothymosin alpha precursor, with a molecular weight of 3108.3 g/mol and CAS number 62304-98-7.
Origin Research supplies lyophilised Thymosin Alpha-1 in 5mg per vial, with documented purity of 99.7% as verified by HPLC and mass spectrometry, accompanied by a third-party Certificate of Analysis. The peptide has been investigated extensively in immunology literature as a thymic regulator, with published research spanning innate and adaptive immune-signalling models. This material is supplied strictly for in-vitro and laboratory research applications and is not intended for human or veterinary use.
Each vial is sealed under inert atmosphere and shipped with ice packs to preserve peptide integrity during worldwide transit. Independent batch-testing data is provided on request, and material is sourced from a GMP-aligned synthesis facility audited for residual solvent and endotoxin parameters relevant to laboratory work.
Mechanism Studied in Research
Thymosin Alpha-1 has been studied in receptor-binding research as a ligand for Toll-like receptor 9 and Toll-like receptor 2 (TLR2) on plasmacytoid dendritic cells and myeloid antigen-presenting cells. Investigations in cell-culture models have characterised downstream activation of MyD88-dependent signalling cascades, leading to NF-kB translocation and modulation of cytokine transcription including interferon-alpha, interleukin-2 and interleukin-12.
In clinical and laboratory literature, Thymosin Alpha-1 has been examined for effects on dendritic-cell maturation pathways, differentiation of CD4+ and CD8+ T-cell subsets, natural-killer-cell cytolytic activity and antigen-presentation processes. Studies in dendritic-cell models have investigated effects on indoleamine 2,3-dioxygenase expression and tryptophan catabolism, parameters relevant to immune-tolerance research.
Additional mechanistic work has explored modulation of regulatory T-cell populations and the Th1/Th2 cytokine balance in murine splenocyte preparations. Thymosin Alpha-1 has also been examined in research on antigen presentation, with documented changes in MHC class-I expression on monocyte-derived dendritic cells following peptide exposure.
Investigators have characterised binding kinetics and intracellular trafficking using fluorophore-tagged analogues, and structural studies have examined the role of the acetylated N-terminus and the central acidic domain in receptor engagement. The polypeptide has been investigated in models of immunosenescence, with publications describing altered thymocyte output and peripheral T-cell receptor diversity following exposure in aged-animal preparations.
Research Applications
Thymosin Alpha-1 has been investigated across multiple laboratory research domains. In immunomodulation research, the peptide has been studied in dendritic-cell maturation assays, T-regulatory-cell expansion models and cytokine-release profiling using peripheral blood mononuclear cell preparations from research donors.
Published investigations have characterised the polypeptide in influenza-vaccine-adjuvant research and in hepatitis-B-vaccine response models, where it was examined as a co-stimulant in primary immunisation studies in animal models. In virology-adjacent laboratory research, Thymosin Alpha-1 has been investigated in murine tumour models and immune-response assays.
Researchers have also examined Thymosin Alpha-1 in lymphocyte proliferation, natural-killer-cell cytotoxicity and macrophage-activation studies. Applications are restricted to laboratory research use only.
Thymosin Alpha-1 has additionally appeared in studies examining immune-cell trafficking, cytokine-network modulation and antigen-presentation efficiency. Research groups have utilised the peptide in experimental inflammation models to evaluate changes in adaptive and innate immune signalling pathways.
Reconstitution Reference
Thymosin Alpha-1 is supplied as a sterile lyophilized powder in a 5mg vial. For laboratory reconstitution, bacteriostatic water is the most common diluent used in research protocols, though sterile water for injection is acceptable for short-term studies.
A standard working example is preparation of a 5mg/ml working stock by adding 1ml of bacteriostatic water to the 5mg vial and directing the diluent down the inner wall of the vial rather than directly onto the peptide cake. The vial is kept at room temperature for several minutes before gentle swirling. Do not shake vigorously, as mechanical agitation may disrupt the polypeptide structure.
Storage and Handling
Lyophilized Thymosin Alpha-1 vials should be stored at -20°C in a sealed container protected from light and humidity. Under these conditions, peptide stability is maintained according to the batch Certificate of Analysis.
Short-term storage at 2°C to 8°C is acceptable for up to 30 days prior to reconstitution. Once reconstituted, working solutions should be stored at 2°C to 8°C and used within 14 to 21 days for optimal peptide integrity in research applications. For longer storage, aliquot reconstituted material into single-use volumes and store at -20°C to avoid repeated freeze-thaw cycles.
References
[2] Garaci E et al. (2007). Thymosin alpha 1: basic research and new therapeutic applications. Annals of the New York Academy of Sciences. PMID 18496948
[3] Sykes AM (2004). Thymalfasin as immune system enhancer for liver disease. Expert Opinion on Biological Therapy. PMID 15264944
[4] Goldstein AL, Badamchian M (2004). Thymosin: chemistry and biological properties in health and disease. Expert Opinion on Biological Therapy.